ISTH Academy

Create Account Sign In
Prothrombin conversion and thrombin decay in patients with cirrhosis—role of prothrombin and antithrombin deficiencies
Author(s): ,
Aurélien Lebreton
Affiliations:
Université Clermont Auvergne, INRAE, UMR 1019 Unité de Nutrition Humaine, Clermont-Ferrand, France
,
Thomas Lecompte
Affiliations:
Université de Lorraine, Faculté de médecine de Nancy, Nancy, France
,
Armand Abergel
Affiliations:
UMR 6602 CNRS-Sigma-Université Clermont Auvergne, Clermont-Ferrand, France
Thomas Sinegre
Affiliations:
Service Hématologie biologique, CHU Clermont Ferrand, Clermont-Ferrand, France
Thomas Sinegre, 1 place Lucie et Raymond Aubrac, CHU Clermont-Ferrand, Service d’hématologie biologique, 63003 Clermont-Ferrand, France.
ISTH Academy. 05/01/24; 422458
Login now to access Regular content available to all registered users.

Access to Premium content is currently a membership benefit.

Click here to join ISTH or renew your membership.

You may also access ISTH content "anytime, anywhere" with the FREE ISTH Academy App for iOS and Android.
Journal Abstract
Discussion Forum (0)
Rate & Comment (0)
Background

Thrombin generation (TG) in the presence of thrombomodulin (TG-TM) in the plasma of patients with cirrhosis (PWC) is tilted toward a hypercoagulable phenotype. Low protein C and elevated factor VIII levels play a role, but other determinants, such as the prothrombin/antithrombin pair, must also be studied.

Objectives

The objectives were (i) to quantitatively assess the subprocesses (prothrombin conversion and thrombin decay) and (ii) to understand the underlying mechanism by studying TG dynamics after prothrombin and antithrombin plasma level correction in PWC.

Methods

We studied TG-TM in plasma samples of 36 healthy controls (HCs) and 41 PWC with prothrombin and antithrombin levels of <70% and after their correction. We initiated coagulation with an intermediate picomolar concentration of tissue factor. We determined the overall thrombin potential, prothrombin conversion, and thrombin decay.

Results

TG-TM was increased in PWC compared with HC due to impaired thrombin inhibition. Indeed, thrombin decay capacity (min−1) decreased from 0.37 (0.35-0.40) in HC to 0.33 (0.30-0.37) in the Child–Turcotte–Pugh A (CTP-A; P = .09), 0.27 (0.26-0.30) in the CTP-B (P < .001), and 0.20 (0.19-0.20) in the CTP-C (P < .001) group. Concomitant correction of prothrombin and antithrombin increased endogenous thrombin potential with prothrombin conversion surpassing thrombin decay. By contrast, when we corrected only antithrombin, TG-TM was normalized and even consistent with a hypocoagulable phenotype in the CTP-C group.

Conclusion

Our results highlight that in PWC, hypercoagulability (evidenced in the presence of TM) is due to impaired thrombin decay, whereas low prothrombin levels do not translate into decreased prothrombin conversion, likely due to altered TM-activated protein C negative feedback.

Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies